Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BI 2536 dosing schedules in advanced or metastatic NSCLC
2005-004005-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BI-2536 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Objective tumor response. Started Nov 2006; status: completed.
02
Drugs
BI-2536
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004005-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004005-28.